J2O-MC-EKBG
Research type
Research Study
Full title
A Phase 3, Randomized, Double-Blind, Placebo-Controlled Study to Investigate the Effect of Muvalaplin on the Reduction of Major Adverse Cardiovascular Events in Adults with Elevated Lipoprotein(a) who have Established Atherosclerotic Cardiovascular Disease or Are at Risk for a First Cardiovascular Event - MOVE-Lp(a)
IRAS ID
1011179
Contact name
Maryna Kvochka
Contact email
Sponsor organisation
Eli Lilly and Company
Research summary
Muvalaplin is being developed to reduce the risk of major adverse cardiovascular events (MACE) ) e.g. stroke, heart attack in adult with elevated levels of Lipoprotein (a) (Lp(a)) who have had a prior atherosclerotic cardiovascular disease (ASCVD) event or are at risk for a first ASCVD event. Elevated Lp(a) is recognised as an important risk factor for cardiovascular disease. However, there are currently no approved treatments for Lp(a) lowering. In recent studies, muvalaplin was shown to effectively reduce Lp(a) and was well tolerated by participants. This study is looking to see if muvalaplin is more effective than placebo in reducing the risk of MACE in adults with elevated Lp(a) and a prior ASCVD event or at risk for a first ASCVD event.
Approximately 10,450 participants (approximately 40% with a prior ASCVD event and 60% at risk for a first ASCVD event) will be randomly assigned in a 1:1 ratio to receive either muvalaplin 120 mg daily or placebo, added to their existing standard-of-care background
medications. The minimum study duration for each participant is expected to be approximately 3.75 years.REC name
London - Fulham Research Ethics Committee
REC reference
25/LO/0467
Date of REC Opinion
27 Nov 2025
REC opinion
Further Information Favourable Opinion